首页> 外文期刊>Nephrology Dialysis Transplantation >Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)
【24h】

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)

机译:西罗莫司对mTOR的抑制作用会减慢常染色体显性多囊肾(ADPKD)的Han:SPRD大鼠的疾病进展

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background. Autosomal dominant polycystic kidney disease (ADPKD) is characterized by dysregulated tubular epithelial cell growth, resulting in the formation of multiple renal cysts and progressive renal failure. To date, there is no effective treatment for ADPKD. The mammalian target of rapamycin (mTOR) is an atypical protein kinase and a central controller of cell growth and proliferation. We examined the effect of the mTOR inhibitor sirolimus (rapamycin) on renal functional loss and cyst progression in the Han:SPRD rat model of ADPKD.
机译:背景。常染色体显性遗传性多囊肾病(ADPKD)的特征是肾小管上皮细胞生长失调,导致形成多个肾囊肿和进行性肾衰竭。迄今为止,尚无有效的ADPKD治疗方法。雷帕霉素(mTOR)的哺乳动物靶标是一种非典型的蛋白激酶,是细胞生长和增殖的主要控制者。我们在ADPKD的Han:SPRD大鼠模型中检查了mTOR抑制剂西罗莫司(雷帕霉素)对肾功能丧失和囊肿进展的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号